Mammalian Polyclonal Immunoglobulin G (IgG) Antibody Market Report 2026

The mammalian polyclonal immunoglobulin g (igg) antibody market size has grown strongly in recent years. It will grow from $1.41 billion in 2025 to $1.51 billion in 2026 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to growth of immunodiagnostic testing, widespread adoption of elisa techniques, increasing biomedical research funding, established use of animal-derived antibodies, rising prevalence of chronic and infectious diseases.

The mammalian polyclonal immunoglobulin g (igg) antibody market size is expected to see strong growth in the next few years. It will grow to $1.96 billion in 2030 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to expansion of precision diagnostics, growth in biomarker-based testing, increasing pharmaceutical r&d investments, rising demand from emerging healthcare markets, continuous development of advanced immunoassay platforms. Major trends in the forecast period include growing use of polyclonal igg in diagnostic assays, rising demand for broad-spectrum antibody reagents, expansion of immunoassay-based testing applications, increased adoption in translational and preclinical research, focus on high-affinity and batch-consistent antibody production.

The rising expenditure on animal health is anticipated to drive the growth of the mammalian polyclonal immunoglobulin G (IgG) antibody market in the coming years. Animal health encompasses comprehensive care and management practices focused on ensuring the well-being and longevity of animals, including pets, livestock, and wildlife. Spending on animal health is growing due to factors such as increasing pet ownership, higher demand for animal-derived products, advancements in veterinary care, stronger human-animal connections, and stricter regulations. Greater investment in animal health enhances the demand for specialized mammalian polyclonal immunoglobulin G (IgG) antibodies, fostering innovation, loyalty, veterinary collaboration, and market expansion within the pet care sector. For example, in March 2023, the American Pet Products Association, a US-based not-for-profit industry organization, reported that pet foods and treats recorded the highest spending at $58.1 billion, reflecting a notable 16.2% increase and marking it as the fastest-growing category. Consequently, the rising expenditure on animal health is expected to drive the growth of the mammalian polyclonal immunoglobulin G (IgG) antibody market.

Major companies operating in the mammalian polyclonal immunoglobulin G (IgG) antibody market are emphasizing the development of innovative products, such as high-throughput antibodies, to accelerate research and therapeutic progress. High-throughput antibodies are produced rapidly and at scale using automated workflows, enabling researchers to screen large numbers of targets efficiently, shorten development timelines, and speed up therapeutic discovery. For example, in July 2024, Twist Bioscience Corporation, a US-based synthetic biology and genomics company, introduced Twist Express Antibodies, CHO, a novel technology aimed at streamlining antibody development. These antibodies are generated from user-defined sequences through Twist’s silicon-based DNA synthesis platform, cloned into IgG scaffold vectors, and produced in CHO cells with turnaround times starting at 13 business days. Each antibody batch provides yield data for screening and quality assurance, making the process cost-effective, customizable, and suitable for high-throughput candidate selection. The antibodies can be used in biotherapeutic drug discovery, research screening, and experimental validation, offering a robust and efficient alternative to conventional lab-based antibody synthesis.

In December 2023, Danaher Corporation, a U.S.-based life sciences and diagnostics innovator, acquired Abcam Limited for an undisclosed amount. The acquisition aimed to strengthen Danaher's capabilities and broaden its market presence, benefiting both the company and its shareholders. Abcam Limited is a U.S.-based manufacturer, distributor, and seller of protein research tools, including rabbit polyclonal GFAP antibodies.

Major companies operating in the mammalian polyclonal immunoglobulin g (igg) antibody market are Thermo Fisher Scientific Inc., Merck KGaA, PerkinElmer Inc., Bio-Rad Laboratories Inc., GeneTex, GenScript Biotech Corporation, Jackson ImmunoResearch Laboratories, Abcam Inc., R&D Systems, Sino Biological, Fortis Life Sciences, OriGene Technologies, Cell Signaling Technology Inc., Cedarlane Labs, Capralogics Inc, Proteintech Group, ProSci LLC, Santa Cruz Biotechnology Inc., Rockland Immunochemicals Inc., Novus Biologicals LLC, Creative Diagnostics, Fitzgerald Industries International Inc.

North America was the largest region in the mammalian polyclonal immunoglobulin G (IgG) antibody market in 2025. The regions covered in the mammalian polyclonal immunoglobulin g (igg) antibody market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the mammalian polyclonal immunoglobulin g (igg) antibody market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have moderately influenced the mammalian polyclonal igg antibody market by increasing costs of imported raw materials, laboratory reagents, and animal-derived inputs. Diagnostic and research segments are most affected, particularly in regions reliant on cross-border sourcing such as north america and europe. Higher costs may impact pricing and procurement cycles for laboratories. However, tariffs are also encouraging local antibody production and regional supply chain development, supporting long-term market stability.

The mammalian polyclonal immunoglobulin g (igg) antibody market research report is one of a series of new reports that provides mammalian polyclonal immunoglobulin g (igg) antibody market statistics, including mammalian polyclonal immunoglobulin g (igg) antibody industry global market size, regional shares, competitors with a mammalian polyclonal immunoglobulin g (igg) antibody market share, detailed mammalian polyclonal immunoglobulin g (igg) antibody market segments, market trends and opportunities, and any further data you may need to thrive in the mammalian polyclonal immunoglobulin g (igg) antibody industry. This mammalian polyclonal immunoglobulin g (igg) antibody market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Mammalian polyclonal IgG antibody is a collection of immunoglobulin G antibodies produced by multiple B cells, providing a wide range of antigen recognition. It is widely used in research, diagnostics, and therapeutics to offer broad-spectrum immunity, which is essential for detecting and neutralizing pathogens and antigens.

The primary products of mammalian polyclonal immunoglobulin G (IgG) antibodies include cardiac markers, metabolic markers, renal markers, and others. Cardiac markers are molecules that indicate heart health and are commonly used in diagnostic tests to evaluate cardiac function and detect heart-related conditions such as myocardial infarction. The types of mammals used include goat, rabbit, horse, mouse, and others. These antibodies have various applications, including enzyme-linked immunosorbent assay (ELISA), immunoturbidometry, immunoelectrophoresis, antibody identification, immunohistochemistry, immunocytochemistry, and western blotting, for end users such as pharmaceutical and biotechnology companies, hospitals, diagnostic centers, and academic and research institutions.

The mammalian polyclonal IgG antibody market consists of sales of infectious disease markers, autoimmune disease markers, tumor markers, and inflammatory markers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.